Pharmaceuticals - Southern Europe

  • Southern Europe
  • The projected revenue in the Pharmaceuticals market for Southern Europe is expected to reach US$40.89bn in 2024.
  • Among the various markets, Oncology Drugs stands out as the largest, with a projected market volume of US$6.91bn in 2024.
  • The market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 3.88%, leading to a market volume of US$49.47bn by 2029.
  • In a global context, United States is anticipated to generate the highest revenue, amounting to US$630.30bn in 2024.
  • In Southern Europe, Italy's pharmaceutical market is experiencing a surge in demand for generic drugs due to cost-saving measures.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Southern Europe has been experiencing growth in recent years.

Customer preferences:
Customers in Southern Europe have been increasingly demanding high-quality and innovative pharmaceutical products. They are willing to pay a premium for products that are effective and have minimal side effects. Additionally, there is a growing demand for personalized medicine and treatments that cater to specific patient needs.

Trends in the market:
Spain, Italy, and Portugal are the largest pharmaceutical markets in Southern Europe. These countries have been experiencing steady growth in the pharmaceutical industry, driven by an aging population, increasing prevalence of chronic diseases, and rising healthcare expenditure. In Spain, the government has been implementing policies to encourage the use of generic drugs, which has led to a decline in the market share of branded pharmaceuticals. Italy has been focusing on reducing healthcare costs by promoting the use of biosimilars. Portugal has been investing in research and development to strengthen its pharmaceutical industry.

Local special circumstances:
Southern Europe has a unique regulatory environment that affects the pharmaceutical industry. Each country has its own regulatory agency that approves and oversees the marketing of pharmaceutical products. Additionally, the healthcare systems in these countries are publicly funded, which means that the government plays a significant role in determining the prices of pharmaceutical products. The economic crisis in the region has also led to austerity measures that have impacted healthcare spending.

Underlying macroeconomic factors:
The pharmaceutical industry in Southern Europe is influenced by macroeconomic factors such as GDP growth, inflation, and unemployment rates. The economic crisis in the region has led to a decline in GDP growth and an increase in unemployment rates, which has affected the purchasing power of consumers. Additionally, the pharmaceutical industry is sensitive to changes in healthcare policies and regulations, which can impact the profitability of pharmaceutical companies. Despite these challenges, the pharmaceutical industry in Southern Europe is expected to continue growing, driven by the increasing demand for innovative and personalized medicine.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)